Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JNJ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsJ&J raises dividend 3.1% to $1.34/share, reports Q1 2026 earnings
Filed April 14, 2026 · Period ending April 14, 2026 · ~1 min read
Key Changes
-
high
Board approved quarterly dividend increase from $1.30 to $1.34 per share (3.1% raise), marking 64th consecutive year of dividend growth and reinforcing Dividend Aristocrat status.
Item 8.01 — Other Events verify on EDGAR → -
high
Company announced Q1 2026 sales and earnings results for quarter ended March 29, 2026 via press release, though specific financial figures not disclosed in the 8-K filing itself.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
medium
Annual dividend rate increases from $5.20 to $5.36 per share, providing income investors with $0.16 additional annual payout per share.
Item 8.01 — Other Events verify on EDGAR → -
medium
Next quarterly dividend payable June 9, 2026 to shareholders of record May 26, 2026; investors must own shares before May 26 ex-dividend date to receive payment.
Item 8.01 — Other Events verify on EDGAR →
Summary
Johnson & Johnson announced two significant developments: Q1 2026 financial results and a dividend increase. The company raised its quarterly dividend 3.1% to $1.34 per share, extending its remarkable 64-year streak of consecutive annual increases—a hallmark of financial stability that distinguishes Dividend Aristocrats. This brings the annualized payout to $5.36 per share, up from $5.20.
The dividend raise signals management's confidence in cash flow generation and commitment to returning capital to shareholders. For income-focused investors, the 64-year track record provides reassurance during uncertain markets. The company also released Q1 2026 earnings covering the period ended March 29, 2026, though the 8-K references a separate press release for detailed figures.
Retail investors should review the full Q1 earnings press release (Exhibit 99.1) for revenue trends, segment performance, and forward guidance. Watch whether the dividend payout ratio remains sustainable as the company navigates its ongoing pharmaceutical and medical device portfolio evolution.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 14, 2026, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 29, 2026.
Johnson & Johnson announced its first quarter 2026 financial results ending March 29, 2026. The 8-K references a press release (Exhibit 99.1) containing the sales and earnings details, but the actual financial figures are not included in the 8-K body itself.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 17, 2026 · How we verify